Opzelura (ruxolitinib cream) / Incyte, Maruho, China Medical System - LARVOL DELTA

Efficacy and Safety of Ruxolitinib Cream Combined With Narrow-Band UVB Phototherapy for Treatment of Vitiligo. (PubMed, J Invest Dermatol) - "Ruxolitinib cream was well tolerated with or without NB-UVB. Patients with <T-VASI25 at Week 12 experienced meaningful improvements in repigmentation with NB-UVB plus ruxolitinib cream combination therapy through Week 48, with no new safety concerns."

Journal • Dermatology • Immunology • Vitiligo

Outcomes of stem cell transplantation in pediatric and adolescent/young adult patients with trisomy 21: A single-center experience (ASH 2025) - "All patients received a myeloablative conditioning with post-transplant cyclophosphamide for graft-versus-host disease (GVHD) prophylaxis...One patient developed steroid refractory grade III skin GvHD requiring prednisone, ruxolitinib, and topical tacrolimus, and experienced eventual improvement with extracorporeal photopheresis... Here we describe three patients with T21 who underwent HSCT for relapsed/refractory leukemia. Two patients are surviving, including one with multiply relapsed disease who had initial graft failure, and remains disease free 2 years and 7 months following HSCT. Toxicities following HSCT were manageable and did not significantly impact engraftment."

Clinical • Acute Kidney Injury • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • CNS Disorders • Developmental Disorders • Endocrine Disorders • Epilepsy • Genetic Disorders • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Mucositis • Nephrology • Pediatrics • Transplantation • TP53

Sustained donor engraftment and clinical remission after hematopoietic cell transplantation for vexas syndrome, but with observed toxicities: Results from a prospective phase II clinical Trial (ASH 2025) - P2 | "Patients with 7/8 HLA orhaploidentical-related donors (cohort 2; n=1) received fludarabine 30 mg/m2 on D-6 to -2,cyclophosphamide 14.5 mg/kg D-6 -5, 200 cGy TBI on D-1, and busulfan on D-4, -3 (daily 3600 uM-min,total 30 mg*h/L). GVHD prophylaxis included post-transplant cyclophosphamide on D+3, +4, MMF toD+35 and sirolimus to D+180...Patients were heavily pre-treated with a median of 4 prior steroid-sparing therapies (range 0-6) andall were steroid-dependent with median prednisone dose pre-HCT of 25mg/day (15-40mg/day)...Four patientsexperienced VEXAS flares around the time of engraftment requiring the use of high-dose steroids +/-tocilizumab, including, fever/altered mental status, labyrinthitis, small bowel inflammation/obstruction,and facial rash...Two patients developed moderatechronic skin GVHD, both of whom have successfully tapered off steroids and remain on ruxolitinib andbelumosudil...At D+30, PD-1+CD4+and PD-1+CD8+, and immature NK cell subfractions were..."

Clinical • IO biomarker • P2 data • Acute Graft versus Host Disease • Aplastic Anemia • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Inflammatory Bowel Disease • Mucositis • Transplantation • B3GAT1 • CCL2 • CD4 • CD8 • IL18 • ISG20 • PD-1 • TNFA

LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis. (PubMed, Front Immunol) - "Ten patients underwent VISIA skin analysis system and severity assessment following topical ruxolitinib treatment...These findings collectively demonstrate that LL37 drives mast cell activation and degranulation in rosacea pathogenesis via TLR2/JAK2/STAT3 pathway activation, while ruxolitinib effectively suppresses this signaling axis. This study provides novel mechanistic insights and therapeutic strategies for rosacea management."

Journal • Dermatitis • Dermatology • Immunology • Inflammation • Rosacea • JAK2 • MYD88 • TLR2

An oral lichen planus-like mouse model driven by IFN-γ signaling and cytotoxic CD8+ T cells. (PubMed, JCI Insight) - "Therapeutic evaluation showed that the JAK inhibitors baricitinib and ruxolitinib effectively reduced disease burden and provided mechanistic insights. In conclusion, this OLP-like mouse model recapitulates key immunopathological and transcriptomic features of human OLP, offering a robust platform for dissecting disease mechanisms and evaluating novel therapeutic strategies."

Journal • Preclinical • Dermatology • Dermatopathology • Immunology • Inflammation • Lichen Planus • CD8 • IFNG

Ruxolitinib in the treatment of vitiligo. The importance of the JAK STAT pathway. (PubMed, Actas Dermosifiliogr) - "This narrative review addresses the immunopathologic processes involved in vitiligo, the role of the JAK-STAT pathway, and the efficacy and safety results of ruxolitinib in the treatment of nonsegmental vitiligo in adult and adolescent patients older than 12 years with facial involvement. In addition, the psychological repercussions and the impact on the quality of life suffered by patients with vitiligo are described."

Journal • Review • Dermatology • Immunology • Vitiligo

Early dermoscopic and confocal features predict response to topical ruxolitinib in nonsegmental vitiligo: A prospective observational study. (PubMed, J Am Acad Dermatol) - No abstract available

Journal • Observational data • Dermatology • Immunology • Vitiligo

Letter: Reduced Staphylococcus aureus Burden on the Skin of Patients With Moderate-to-Severe Chronic Hand Dermatitis Treated With Topical 1.5% Ruxolitinib. (PubMed, Dermatitis) - No abstract available

Journal • Contact Dermatitis • Dermatitis • Dermatology • Immunology

Topical Ruxolitinib and Delgocitinib Versus Systemic JAK Inhibitors: A Comparative Safety Review. (PubMed, Int J Mol Sci) - "Taken together, these findings suggest that t-JAKi may represent safer alternatives to s-JAKi for selected patients with localized inflammatory skin diseases, particularly those with comorbidities or heightened systemic risk. Long-term studies and real-world evidence are needed to confirm sustained safety and guide their optimal integration into clinical practice."

Adverse events • Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Inflammation • Respiratory Diseases

Efficacy and Safety of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis: Results From TRuE-AD4, a Phase 3b, Randomized, Double-Blind, Vehicle-Controlled Study (ISDS 2025) - P3 | "In adults with moderate AD post-TCS and -TCI, who may otherwise be eligible for systemic therapy, 1.5% ruxolitinib cream significantly improved clinical signs of AD, rapidly improved itch, and was well tolerated. Ruxolitinib cream may therefore be an option to delay or prevent progression to systemic therapy in AD."

Clinical • P3 data • Acne Vulgaris • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Itch of Dermatomyositis treated with topical JAK inhibitor (ISDS 2025) - "Herein, we present two cases of refractory DM-associated pruritus successfully treated with Ruxolitinib, a topical JAK inhibitor (JAKi): a 44-year-old woman and the a 71-year-old woman, both of whom experienced significant improvement in pruritus after the use of topical Ruxolitinib...Ann Transl Med. 2021; 9(5):441."

Atopic Dermatitis • Dermatitis • Dermatology • Dermatomyositis • Immunology • Inflammation • Myositis • Pruritus • Rheumatology

Trends in Prescribing and Costs of Topical Ruxolitinib Among U.S. Dermatologists (ISDS 2025) - "CPD rose modestly each year, from $66.46 in 2021 to $74.32 in 2023, which is in line with inflation. These findings suggest rapid uptake and aggregate costs, highlighting the need for ongoing monitoring of utilization, costs, and access, particularly as the use of topical ruxolitinib increases in the treatment of inflammatory skin diseases."

Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Vitiligo

Inhibition of the JAK/STAT pathway prevents acantholysis in pemphigus (ISDS 2025) - "Finally, a pemphigus lesion in a steroid-unresponsive patient was treated with topical ruxolitinib, the clinical response and epidermal STAT activation were assessed. Our investigation revealed that loss of epidermal integrity by AK23 is accompanied by increased expression of cytokines (IL6, IL19, IL24, IFNE) and anti-Dsg antibodies activate STAT1 and STAT3. Administration of JAK inhibitors in vitro and in vivo prevented anti-Dsg antibodies-induced STAT activation and cell dissociation in keratinocytes."

Dermatology • Immunology • IL6 • STAT1 • STAT3

A humanized xenotransplant model reveals IgG4 and HSP70 as co-drivers of vitiligo and predicts clinical drug responses (ISDS 2025) - "Therapeutically, topical tacrolimus and ruxolitinib cream produced repigmentation in ∼30% and ∼70% of lesions respectively, consistent with clinical experience; however, epidermal TRM persisted after ruxolitinib, retaining cytokine competence. Senescence and mitochondrial dysfunction are early, supportive features that increase model relevance to human disease. The platform therefore provides a translationally relevant tool for dissecting mechanisms and testing therapies that target humoral-cellular cooperation, danger signaling, and cellular senescence in vitiligo."

Clinical • Dermatology • Immunology • Metabolic Disorders • Transplantation • Vitiligo • CAT • CD8 • IFNA1 • IFNG • IL15 • IL18 • ITGAX • MICA • NKG2D • SIRT1 • Tyrosinase

THE PATIENT JOURNEY IN VITILIGO. (PubMed, Dermatology) - "Ruxolitinib cream, a JAK inhibitor, has recently emerged as the first approved targeted therapy for non-segmental vitiligo...Optimizing the patient journey through structured care networks and early specialist involvement is essential to improving quality of life and clinical outcomes. With the advent of novel treatments, healthcare systems must adapt to provide more coordinated, patient-centered care for individuals living with vitiligo."

Journal • Review • CNS Disorders • Dermatology • Immunology • Mood Disorders • Psychiatry • Vitiligo

Use of Ruxolitinib Cream Results in Economic Benefits Compared with Dupilumab in Treatment of Patients with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy. (PubMed, Dermatol Ther (Heidelb)) - "This model demonstrates that 1.5% ruxolitinib cream reduces treatment costs by over 80% compared to dupilumab in patients with moderate AD eligible for systemic therapy. Combined with comparable efficacy, these savings position ruxolitinib cream as a cost-effective treatment option."

HEOR • Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

TRuE-PN2: A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) (clinicaltrials.gov) - P3 | N=190 | Completed | Sponsor: Incyte Corporation | Active, not recruiting ➔ Completed

Trial completion • Immunology • Prurigo Nodularis

Ruxolitinib Cream Demonstrated Rapid Reductions in Itch and Atopic Dermatitis Signs That Correlated With Biomarkers. (PubMed, J Invest Dermatol) - P2 | "There were no serious treatment-emergent adverse events. In summary, patients with AD who applied 1.5% ruxolitinib cream experienced rapid and sustained improvement in itch and clinical improvements that correlated with changes in AD biomarkers."

Biomarker • Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

TRUX-LST: Topical Ruxolitinib Evaluation in Immune-related Lichenoid Skin-Toxicities (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: University of Zurich | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2025 ➔ May 2026 | Trial primary completion date: Nov 2025 ➔ Mar 2026

Enrollment open • IO biomarker • Trial completion date • Trial primary completion date • Dermatology

Topical Ruxolitinib as an Effective Therapy for Vitiligo-Like Lesions Induced by Anti-PD-1 Therapy. (PubMed, Int J Dermatol) - No abstract available

Journal • Dermatology • Immunology • Vitiligo

Efficacy and Safety of Ruxolitinib Cream in Patients With Mild to Moderate Hidradenitis Suppurativa: Results From a Randomized, Double-Blind, Vehicle-Controlled Phase 2 Study. (PubMed, J Am Acad Dermatol) - "Ruxolitinib cream demonstrated greater clinical benefit versus vehicle in patients with milder HS and had a well-tolerated safety profile."

Clinical • Journal • P2 data • Dermatology • Hidradenitis Suppurativa • Immunology

Topical 1.5% ruxolitinib cream for facial refractory segmental vitiligo: A retrospective single-center study. (PubMed, JAAD Int) - No abstract available

Journal • Retrospective data • Dermatology • Immunology • Vitiligo

Topical ruxolitinib ± oral baricitinib in the treatment of active non-segmental vitiligo: A retrospective analysis. (PubMed, J Eur Acad Dermatol Venereol) - No abstract available

Journal • Retrospective data • Dermatology • Immunology • Vitiligo

Successful treatment of annular lichenoid dermatitis of youth with topical ruxolitinib. (PubMed, JAAD Case Rep) - No abstract available

Journal • Dermatitis • Dermatology • Immunology

Topical Ruxolitinib for Chronic Cutaneous GvHD: Promising Results of a Phase 2 Clinical Trial (ASH 2023) - "This is the first study to characterize the effect of topical JAK1/2 blockade on cutaneous cGVHD. Ruxolitinib 1.5% cream was safe and effective compared to placebo in treating cutaneous nonsclerotic and superficially sclerotic GvHD. Responders to ruxolitinib cream had genomic signature differences in IL-12 signaling from nonresponders."

Clinical • IO biomarker • P2 data • Acute Graft versus Host Disease • Atopic Dermatitis • Chronic Graft versus Host Disease • Dermatitis • Dermatology • Dermatopathology • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Lichen Planus • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Vitiligo • IL12A • JAK1 • JAK2 • SNRPA1 • SOD2 • ZAP70